Strelia advises Newton Biocapital, who acted as lead investor in the 20 million series A investment round in NeuVasQ Biotechnologies, a spin-off of the ULB active in the fight against neurological disorders.

Strelia’s Corporate team, led by Laurent Verhavert and Julie Lo Bue, has advised Newton Biocapital, a life sciences investment fund active in Europe and Japan, in the framework of the series A financing round in NeuVasQ Biotechnologies, a spin-off of the ULB specialized in the development of novel therapies for brain disorders.,, Newton Biocapital acted as lead investor and was joined by public and private investment partners for this successful series A round..

Press article : https://www.lecho.be/entreprises/pharma-biotechnologie/neuvasq-leve-20-millions-d-euros-contre-les-maladies-neurologiques/10315183.html?_s%E2%80%A6